VOLITIONRX LTD — Director's Dealing 2022

Jun 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-06-23-05:00

Reporting Person: Rootsaert Rodney Gerard (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-23-05:00	Common Stock	A	13068	—	Acquired	40502	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-23-05:00	Stock Option (Right to Buy)	$3.40	A	24083	Acquired	2031-08-03-05:00	Common Stock (24083)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1007718	Indirect

Footnotes

F1: On August 3, 2021, the reporting person was awarded 20,104 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,068 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,534 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,036 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

F2: The shares of common stock are held directly by Concord International, Inc. Mr. Rootsaert is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.

F3: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,083 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 12,042 shares and 12,041 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 12,967 shares subject to the award previously vested and remain subject to time-based vesting.